• 1
    Purvis D., Kirby R. Systemic inflammatory response syndrome: Septic shock. Vet Clin North Am Small Anim Pract 1994;24:12251246.
  • 2
    Levi M., ten Cate H., van der Poll T., et al. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1993;270:975979.
  • 3
    Gando S., Kameue T., Nanzaki Y., et al. Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome. Thromb Haemost 1996;75:224228.
  • 4
    Morris DD, Beech J. Disseminated intravascular coagulation in six horses. J Am Vet Med Assoc 1983;183:10671072.
  • 5
    Thomson GW, McSherry BJ, Valli VEO. Endotoxin induced disseminated intravascular coagulation in cattle. Can J Comp Med 1974; 38:457466.
  • 6
    Taylor FB. The inflammatory-coagulant axis in the host response to gram-negative sepsis: Regulatory roles of proteins and inhibitors of tissue factor. New Horiz 1994;2:555565.
  • 7
    Hoffman H., Seibeck M., Spannagl M., et al. Effects of recombinant hirudin, a specific inhibitor of thrombin, on endotoxin-induced intravascular coagulation, and acute lung injury in pigs. Am Rev Respir Dis 1990;142:782788.
  • 8
    Levi M., van Der Poll T., Ten Cate H., et al. The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxemia. Eur J Clin Invest 1997;27:29.
  • 9
    Warr T., Rao VM, Rapaport SI. Disseminated intravascular coagulation in rabbits induced by administration of endotoxin or tissue factor. Blood 1990;75:14811489.
  • 10
    Kalter EJ, Daha MR, ten Cate JW, et al. Activation and inhibition of Hageman factor-dependent pathways and the complement system in uncomplicated bacteremia or bacterial shock. J Infect Dis 1985;151:10191027.
  • 11
    Nuijens JH, Huijbregts CCM, Eerenberg-Belmer AJM, et al. Quantification of plasma factor XIIa-Cl-inhibitor and kallikrein-Cl-inhibitor complexes in sepsis. Blood 1988;72:184188.
  • 12
    Nemerson Y. The tissue factor pathway of blood coagulation. Sem Hematol 1992;29:170176.
  • 13
    Taylor FB Jr, Chang A., Ruf W., et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991; 33: 127134.
  • 14
    Pixley RA, De La Cadena R., Page JD. Activation of the contact system in lethal hypotensive bacteremia in a baboon model. Am J Pathol 1992;140:897906.
  • 15
    Rashid J., Weiss DJ, Bach R., et al. Role of tissue factor in intraalveolar fibrin deposition and coagulopathy associated with bovine pneumonic pasteurellosis. Am J Vet Res In press.
  • 16
    Car BD, Slauson DO, Suyemoto MM, et al. Expression and kinetics of induced procoagulant activity in bovine pulmonary alveolar macrophages. Exp Lung Res 1991;17:939957.
  • 17
    Car BD, Suyemoto MM, Neilsen NR, et al. The role of leukocytes in the pathogenesis of fibrin deposition in bovine acute lung injury. Am J Pathol 1991;138:11911198.
  • 18
    Halvorsen H., Olsen JO, Osterud B. Granulocytes enhance LPS-induced tissue factor activity in monocytes via an interaction with platelets. J Leukoc Biol 1993;54:275282.
  • 19
    Wharram BL, Fitting K., Kunkel SL, et al. Tissue factor expression in endothelial cell/monocyte cocultures stimulated by lipopolysacchride and/or aggregated IgG. J Immunol 1991; 146:14371445.
  • 20
    Morrison DC, Rudback JA. Endotoxin-cell membrane interactions leading to transmembrane signaling. Contemp Top Mol Immunol 1981;8:187218.
  • 21
    Dean DF, Carrol RC, Bochler PN, et al. Endotoxin-induced signal transduction pathways in bovine alveolar macrophages. Vet Pathol 1993;30:476.
  • 22
    Yoo HS, Maheswaran SK, Lin G., et al. Induction of inflammatory cytokines in bovine alveolar macrophages following stimulation with Pasteurella haemolytica. Infect Immun 1995; 63: 381388.
  • 23
    Henry MM, Moore JN. Endotoxin-induced procoagulant activity in equine peripheral blood monocytes. Circ Shock 1988;26:297309.
  • 24
    Rashid J., Weiss DJ, Maheswaran SK, et al. In vitro expression and inhibition of procoagulant activity produced by bovine alveolar macrophages and peripheral blood cells. Vet Res Commun In press.
  • 25
    Vilcek J., Le J. The cytokine network. Immunol Today 1989; 10:299304.
  • 26
    van Der Poll T., Levi M., Hack CE, et al. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med 1994;179:12531259.
  • 27
    Stouthard J., Levi M., Hack CE, et al. Interleukin 6 stimulates coagulation but not fibrinolysis in humans. Thromb Haemost 1996; 76: 738742.
  • 28
    Drake TA, Cheng J., Chang AI, et al. Expression of tissue factor, thrombomodulin, and E-selectin in baboons with lethal Escherichia coli sepsis. Am J Pathol 1993;142:14581570.
  • 29
    Conkling PR, Greenberg CS, Weinberg JB. Tumor necrosis factor induces tissue factor-like activity in human leukemia cell line U937 and peripheral blood monocytes. Blood 1988;72:128133.
  • 30
    Rashid J., Weiss DJ, Murtaugh MP, et al. Expression of tissue factor in experimental bovine pneumonic pasteurellosis and endotoxemia. Vet Clin Pathol In press.
  • 31
    Whiteley LO, Maheswaran SK, Weiss DJ, et al. Immunohistochemical localization of Pasteurella haemolytica A1 -derived endotoxin, leukotoxin and capsular polysaccharide in experimental bovine pasteurella pneumonia. Vet Pathol 1990;27:150161.
  • 32
    Weiss DJ, Bauer MC, Whiteley LO, et al. Changes in blood and bronchoalveolar lavage fluid components in calves with experimentally induced pneumonic pasteurellosis. Am J Vet Res 1991; 52: 337344.
  • 33
    Breider MA, Walker RD, Hopkins FM, et al. Pulmonary lesions induced by P. haemolytica in neutrophil sufficient and neutrophil deficient calves. Can J Vet Res 1988; 52: 205209.
  • 34
    Esmon CT. Cell mediated events that control blood coagulation and vascular injury. Annu Rev Cell Biol 1993;9:126.
  • 35
    Borrelli E., Giomarelli P., Chiara O., et al. Lipid peroxidation and lung ultrastructural changes in an experimental model of leukocyte-mediated lung injury. Lung 1990;168:3542.
  • 36
    Smedly LA, Tonnesen MG, Sandhaus RA, et al. Neutrophilmediated injury to endothelial cells. J Clin Invest 1986;77:12331243.
  • 37
    Fletcher DS, Osinga DG, Keenan K., et al. An inhibitor of leukocyte elastase prevents immune complex-mediated hemorrhage in the rat lung. J Pharmacol Exp Ther 1995;274:548554.
  • 38
    Breider MA, Yang Z. Tissue factor expression in bovine endothelial cells induced by Pasteurella haemolytica lipopolysaccharide and interleukin-1. Vet Pathol 1994;31:5560.
  • 39
    Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163:740745.
  • 40
    Conway EM, Rosenberg RD. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol 1988;8:55885592.
  • 41
    Redl H., Schlag G., Schieber A. Thrombomodulin release in baboon sepsis: Its dependence on the dose of Escherchia coli and the presence of tumor necrosis factor. J Infect Dis 1995;171:15221527.
  • 42
    Taylor FB, Chang A., Ferrel G., et al. C4b-Binding protein exacerbates the host response to Escherichia coli. Blood 1991; 78: 357363.
  • 43
    Weiss DJ, Geor RJ, Johnston G., et al. Microvascular thrombosis associated with onset of acute laminitis in ponies. Am J Vet Res 1994; 55:606612.
  • 44
    Gawaz M., Fateh-Moghadam, Pilz G, et al. Platelet activation and interaction with leukocytes in patients with sepsis or multiple organ failure. Eur J Clin Invest 1995;25:843851.
  • 45
    Ono S., Mochizuki H., Tamakuma S. A clinical study on the significance of platelet-activating factor in the pathophysiology of septic disseminated intravascular coagulation in surgery. Am J Surg 1996; 171:409415.
  • 46
    Nash GB. Adhesion between neutrophils and platelets: A modulator of thrombotic and inflammatory events. Thromb Res 1994;74: S3S11.
  • 47
    Rinder HM, Bonan JL, Rinder CS, et al. Dynamics of leukocyte-platelet adhesion in whole blood. Blood 1991;87:27301737.
  • 48
    Gawaz M., Fateh-Moghadam S., Pilz G., et al. Severity of multiple organ failure (MOF) but not sepsis correlates with irreversible platelet degranulation. Infection 1995;23:1627.
  • 49
    Marcus AJ. Thrombosis and inflammation as multicellular processes: Significance of cell-cell interactions. Semin Hematol 1994; 31: 261269.
  • 50
    Jarvis GE, Evans RJ. Endotoxin-induced platelet aggregation in heparinized equine whole blood. Res Vet Sci 1994;57:317324.
  • 51
    Shinozaki K., Kawasaki T., Kambayashi J., et al. Species differences in platelet aggregation induced by platelet-activating factor (PAF). Methods Find Exp Clin Pharmacol 1992;14:663665.
  • 52
    Foster AP, Lees P., Andrews MJ, et al. Effects of WEB 2086, an antagonist to the receptor for platelet-activating factor (PAF), on PAF-induced responses in the horse. Equine Vet J 1992;24:203207.
  • 53
    Yamanaka S., Iwao H., Yukimura T., et al. Effects of the platelet-activating antagonist, TCV-309, and the cyclo-oxygenase inhibitor, ibuprofen, on the haemodynamic changes in canine experimental endotoxic shock. Br J Pharmacol 1993;110:15011507.
  • 54
    Biffl WL, Moore EE, Moore FA, et al. Interleukin-6 stimulates neutrophil production of platelet-activating factor. J Leukoc Biol 1996; 59:569574.
  • 55
    Shattil S., Cunningham M., Hoxie JA. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 1987;70:307315.
  • 56
    Abrams CS, Ellison N., Budzyski AZ, et al. Direct detection of activated platelets and platelet-derived microparticles in humans. Blood 1990;75:128138.
  • 57
    Spangenberg P. Adhesion of activated platelets to polymorphonuclear leukocytes. Thromb Res 1994;74:S35S44.
  • 58
    Weiss DJ, Evanson OA. Detection of activated platelets and platelet-leukocyte aggregates in horses. Am J Vet Res 1997;58:823827.
  • 59
    Johnstone I., Crane S. Hemostatic abnormalities in equine colic. Am J Vet Res 1986;46:356358.
  • 60
    Dosquet C., Weill D., Wautier JL. Cytokines and thrombosis. J Cardiovas Pharmacol 1995;25:S13S19.
  • 61
    Carr C., Bild GS, Chang ACK, et al. Recombinant E. coli-de-rived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon gram-negative model of septic shock. Circ Shock 1995; 44: 126137.
  • 62
    Henry MM, Moore JN. Whole blood re-calcification time in equine colic. Equine Vet J 1991;23:303308.
  • 63
    Wada H., Nakase T., Nakaya R., et al. Elevated plasma tissue factor antigen levels in patients with disseminated intravascular coagulation. Am J Hematol 1994;45:232236.
  • 64
    Asakura H., Kamikubo Y., Goto A., et al. Role of tissue factor in disseminated intravascular coagulation. Thromb Res 1995;80:217224.
  • 65
    Marcus AJ. Thrombosis and inflammation as multicellular process: Pathophysiologic significance of transcellular metabolism. Blood 1990;76:19031907.
  • 66
    Bazzioni G., Dejana E., Maschio AD. Platelet-neutrophil interactions. Possible relevance in the pathogenesis of thrombosis and inflammation. Haematologica 1991; 76: 491499.
  • 67
    Gawaz MP, Bogner C. Changes in platelet membrane glycoproteins and platelet-leukocyte interaction during hemodialysis. Clin Investig 1994;72:424429.
  • 68
    Prasse KW, Topper MJ, Moore JN, et al. Analysis of hemostasis in horses with colic. J Am Vet Med Assoc 1993;203:685693.
  • 69
    Topper MJ, Prasse KW. Use of enzyme-linked immunosorbent assay to measure thrombin-antithrombin III complexes in horses with colic. Am J Vet Res 1996;57:456459.
  • 70
    Darien BJ, Potempa J., Moore JN, et al. Antithrombin III activity in horses with colic: An analysis of 46 cases. Equine Vet J 1991; 23: 211214.
  • 71
    Sandholm M., Vidovic A., Puotunen-Reinert S., et al. D-Dimer improves the prognostic value of combined clinical and laboratory data in equine gastrointestinal colic. Acta Vet Scand 1995;36:255272.
  • 72
    Meyers K., Reed S., Keck M., et al. Circulating endotoxin-like substances (s) and altered hemostasis in horses with gastrointestinal disorders: An interim report. Am J Vet Res 1982;43:22332237.
  • 73
    Duncan SG, Meyers KM, Reed SM, et al. Alterations in coagulation and hemograms of horses given endotoxin for 24 hours via hepatic portal infusion. Am J Vet Res 1985;46:12871293.
  • 74
    Ward DS, Fessler JF, Bottoms GD, et al. Equine endotoxemia: Cardiovascular, eicosanoid, hematologic, blood chemical, and plasma enzyme alterations. Am J Vet Res 1987;48:11501156.
  • 75
    Morris DD. Endotoxemia in horses—A review of cellular and humoral mediators involved in its pathogenesis. J Vet Intern Med 1991;5:167181.
  • 76
    Jarvis GE, Evans RJ. Endotoxin-induced platelet aggregation in heparinized equine whole blood in vitro. Res Vet Sci 1994;57:317324.
  • 77
    Morris DD, Whitlock RH, Corbeil LB. Endotoxemia in horses: Protection provided by antiserum to core lipopolysaccharide. Am J Vet Res 1986;47:544550.
  • 78
    Durando MM, Mackay RJ, Skelley LA. Effects of polymyxin B and Salmonella typhimurium antiserum on horses given endotoxin intravenously. Am J Vet Res 1994;55:921927.
  • 79
    Silver GM, Fink MR. Possible roles for anti-or pro-inflammatory therapies in the management of sepsis. Surg Clin North Am 1994; 74:711724.
  • 80
    Lynn WA, Golenbock DT. Lipopolysaccharide antagonists. Immunol Today 1992;13:271276.
  • 81
    Suffredini AE. Current prospects for the treatment of clinical sepsis. Crit Care Med 1994;22:S12S18.
  • 82
    Ziegler EJ, Fisher CJ Jr, Sprung CL, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: A randomized, double-blind, placebo-controlled trail. N Engl J Med 1992;327:890891.
  • 83
    Greenman RL, Schein RMH, Martin MA, et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 1991;266:10971102.
  • 84
    van der Poll T., Lowry SF. Tumor necrosis factor in sepsis: Mediator of multiple organ failure or essential part of host defense Shock 1995;3:112.
  • 85
    Windsor AC, Mullen PG, Walsh CJ, et al. Delayed tumor necrosis factor blockade attenuates pulmonary dysfunction and metabolic acidosis associated with experimental gram-negative sepsis. Arch Surg 1994;129:8089.
  • 86
    Russel DA, Tucker KK, Chinookoswong N., et al. Combined inhibition of interleukin-1 and tumor necrosis factor in rodent endotoxemia: Improved survival and organ failure. J Infect Dis 1995; 171: 15281538.
  • 87
    Pennington JE. Therapy with antibody to tumor necrosis factor in sepsis. Clin Infect Dis 1993;17:S515S519.
  • 88
    Abraham E., Wunderink R., Silverman H., et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. JAMA 1995;273:934941.
  • 89
    Lee JC, Prabhakar U., Griswold DE, et al. Low-molecular weight TNF biosynthesis inhibitors: Strategies and prospective. Circ Shock 1995;44:97103.
  • 90
    Carrick JB, Morris DD, Moore JN. Administration of a receptor antagonist for platelet-activating factor during equine endotoxemia. Equine Vet J 1993;25:152157.
  • 91
    King JN, Gerring EL. Antagonism of endotoxin-induced disruption of equine gastrointestinal motility with the platelet-activating factor antagonist WEB 2086. J Vet Pharmacol 1990;13:333339.
  • 92
    Wilson DV, Patterson JS, Stick JA, et al. Histologic and ultra-structural changes after large-colon torsion, with and without use of a specific platelet-activating factor antagonist (WEB 2086), in ponies. Am J Vet Res 1994;55:681688.
  • 93
    Moore BR, Hinchcliff KW. Heparin: A review of its pharmacology and therapeutic use in horses. J Vet Intern Med 1994;8:2635.
  • 94
    Belknap J., Moore J. Evaluation of heparin for prophylaxis of equine laminitis: 71 cases (1980–1986). J Am Vet Med Assoc 1989; 1995:505507.
  • 95
    Moore J., Mahaffey E., Zboran M. Heparin-induced agglutination of erythrocytes in horses. Am J Vet Res 1987;58:6871.
  • 96
    Monreal L., Villatoro AJ, Monreal M., et al. Comparison of the effects of low-molecular-weight and unfractionated heparin in horses. Am J Vet Res 1995;56:12811285.
  • 97
    Weitz JI, Hudoba M., Massel D., et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin Ill-independent inhibitors. J Clin Invest 1990;86:385391.
  • 98
    Gomi K., Zushi M., Honda G., et al. Antithrombotic effects of recombinant human thrombomodulin in thrombin-induced thromboembolism in mice. Blood 1990;75:13961399.
  • 99
    Ono M., Nawa K., Marumoto Y. Antithrombotic effects of recombinant human soluble thrombomodulin in a rat model of vascular shunt thrombosis. Haemost Thromb 1994;72:421425.
  • 100
    Mohri M., Oka M., Aoki Y., et al. Intravenous extended infusion of recombinant human soluble thrombomodulin prevented tissue factor-induced disseminated intravascular coagulation in rats. Am J Hematol 1994;45:298303.
  • 101
    Hirsh J., Dalen JE, Fuster V., et al. Aspirin and other plateletactive drugs. Chest 1995;108:S247S298.
  • 102
    Weitz JI, Califf RM, Ginsberg JS, et al. New antithrombotics. Chest 1995; 108:S471486.
  • 103
    Weiss DJ, Evanson OA, Wells RE. Evaluation of arginineglycine-aspartate-containing peptides as inhibitors of equine platelet function. Am J Vet Res 1997;58:457460.